Introduction
============

Stroke is a heterogeneous disease with different etiologies, and may present with or without underlying arterial pathologies^[@bib1]--[@bib5])^. Thus, the benefits of statins may be different depending on the stroke subtype. The Japan Statin Treatment Against Recurrent Stroke (J-STARS) study was conducted to examine whether pravastatin (10 mg/day) reduces recurrence of stroke in non-cardioembolic ischemic stroke patients. The main results of the J-STARS study showed that although the rates of total stroke and transient ischemic attack (TIA) in patients treated with pravastatin were similar to untreated individuals, the incidence of atherothrombotic stroke was lower^[@bib6])^. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed that atorvastatin treatment was associated with a 16% reduction in the risk of recurrent stroke^[@bib7])^. The subjects in SPARCL trial were enrolled within 6 months after stroke onset. In general, there is a frequent stroke recurrence within the first year of the initial stroke event. In the J-STARS study patients were recruited for up to 3 years after the initial stroke onset. We hypothesized that the timing of statin treatment may affect its ability to prevent recurrent strokes. In the present study, we evaluated differences of early (within 6 months) or late (after 6 months) pravastatin treatment benefits on the incidence of stroke or TIA, as well as atherothrombotic stroke and other stroke subtypes.

Methods
=======

Patients
--------

Details of the rationale, study design, characteristics of the participants, and principal results of the J-STARS study have been published elsewhere^[@bib6],\ [@bib8],\ [@bib9])^. Briefly, patients aged 45 to 80 years with a history of non-cardioembolic ischemic stroke within the preceding 1 month to 3 years were enrolled from 123 centers between March 2004 and February 2009. All patients had a total cholesterol level between 4.65 to 6.21 mmol/L (180 to 240 mg/dL) at enrollment, without use of statins. The major exclusion criteria included cerebral infarction of determined rare etiology, infarction associated with catheterization or surgery, and preferred use of statins for the treatment of co-morbid coronary artery disease. This study was conducted under the health insurance system of Japan, in accordance with the Declaration of Helsinki and the Ethical Guidelines on Clinical Studies of the Ministry of Health, Labor, and Welfare of Japan. This clinical trial is registered at [ClinicalTrials.gov](ClinicalTrials.gov) with the number NCT00221104.

Procedures
----------

Patients were enrolled via a web-based registration and follow-up system provided by the data center, which automatically judged eligibility of each patient and randomly assigned them to pravastatin (10 mg/day) or control group (1:1 allocation). In the randomization process, prevalence rates of stroke subtype (atherothrombotic stroke), high blood pressure (BP) (≥ 150/90 mmHg), and comorbidity of diabetes were dynamically balanced between the two groups. In the pravastatin group, the administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6.21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs was allowed only when such reinforcements were insufficient, based on the decision of the primary physician. Use of statins other than pravastatin was prohibited. In the control group, administration of any statin was prohibited.

After randomization, patients were followed up at 2 and 6 months, and annually after that until the study completion. When patients had recurrent stroke or other vascular events, such event information was sent to the data center. Treatment compliance was monitored at every clinical visit.

The primary endpoint was the onset of stroke and TIA. Secondary endpoints contained the onset of each stroke subtype, myocardial infarction, vascular accident, death, and hospitalization. The diagnostic criteria for each stroke subtype, TIA, myocardial infarction, and vascular accidents were shown in previous reports^[@bib6],\ [@bib8],\ [@bib10])^. Particularly, stroke and other vascular events were adjudicated by the central event evaluation committees. For the adjudication of events, the final decision was made by consensus of all committee members. Additionally, correctness of all event adjudication was verified by a local neurologist or cardiologist in each participating center, by collating it with the patient medical records.

Statistical Analysis
--------------------

In the current post-hoc analyses, we evaluated whether early (within 6 months) or late (after 6 months) pravastatin treatment had differential efficacy with respect to the incidence of atherothrombotic stroke, which was significantly reduced with pravastatin treatment in the J-STARS study^[@bib6])^, as well as with regard to stroke and TIA, and other stroke subtypes. The data were expressed as the mean ± standard deviation for continuous variables and as frequencies and percentages for discrete variables. Comparisons of the clinical characteristics were made using analysis of variance (for continuous variables) or *χ*^[@bib2]^ tests (for discrete variables). In accordance with the intention-to-treat (ITT) principle, the efficacy analysis set was defined as the ITT population, and included all randomized patients. The cumulative incidences of time to the first event were estimated by the Kaplan-Meier method. The cumulative incidence rates were analyzed using the person-year method. The cumulative incidence curves for the two groups were compared using a log-rank test adjusted for the stratification factors at randomization: i.e., stroke subtype at baseline (atherothrombotic stroke vs. others), high BP (≥ 150/90 mmHg vs. not), and diabetes mellitus (absence vs. presence). The Cox proportional hazard model was used to estimate the hazard ratio (HR) and the 95% confidence interval (CI) by adjusting such stratification factors. All analyses were conducted using SAS version 9.3 (Cary, NC, USA). The level of significance was set at *p* \< 0.05 (2-tailed).

Results
=======

The 1578 patients were randomly allocated to the pravastatin or control group (793 vs. 785 subjects). There were 426 subjects enrolled within 6 months after stroke onset and 367 subjects enrolled later than 6 months in the pravastatin group. In the control group, 417 subjects were enrolled within 6 months after stroke onset and 368 subjects were enrolled later than 6 months. The baseline characteristics of subjects are shown in **[Table 1](#T1){ref-type="table"}**; there were no significant differences in variables among the four groups, except use of anti-hypertensive agents, high-density lipoprotein (HDL) cholesterol, and systolic BP. Specifically, use of anti-hypertensive agents was less, HDL cholesterol was lower, and systolic BP was higher in groups enrolled within 6 months than later than 6 months (*p* \< 0.001, *p* \< 0.001, and *p* = 0.003 respectively).

###### Baseline characteristics

  Characteristic                                                          Pravastatin *n* = 793   Control *n* = 785                  
  ----------------------------------------------------------------------- ----------------------- ------------------- -------------- --------------
  Age, years                                                              65.9 ± 8.5              66.3 ± 8.3          66.0 ± 8.8     66.7 ± 8.21
  Male, n (%)                                                             292 (68.5)              253 (68.9)          285 (68.3)     257 (69.8)
  Body mass index, kg/m^2^                                                23.7 ± 3.2              24.0 ± 3.0          23.7 ± 3.1     23.5 ± 3.0
  Hypertension, n (%)                                                     309 (72.5)              287 (78.2)          320 (76.7)     284 (77.2)
  Diabetes mellitus, n (%)                                                104 (24.4)              81 (22.1)           99 (23.7)      85 (23.1)
  Smoker, n (%)                                                           220 (51.6)              206 (56.1)          213 (51.1)     207 (56.3)
  Ischemic stroke subtype                                                                                                            
      Atherothrombotic stroke, n (%)                                      101 (23.7)              94 (25.6)           107 (25.7)     99 (26.9)
      Lacunar infarction, n (%)                                           271 (63.6)              231 (62.9)          274 (65.7)     230 (62.5)
      Undetermined etiology, n (%)                                        54 (12.7)               42 (11.4)           36 (8.6)       39 (10.6)
  Use of antiplatelet agents, n (%)                                       395 (92.7)              328 (89.4)          393 (94.2)     322 (87.5)
  Use of anti-hypertensive agents, n (%)[\*](#tf1){ref-type="table-fn"}   228 (53.5)              248 (67.6)          242 (58.0)     235 (63.9)
  Total cholesterol, mmol/L                                               5.45 ± 0.43             5.42 ± 0.45         5.42 ± 0.43    5.43 ± 0.42
  HDL cholesterol, mmol/L[\*](#tf1){ref-type="table-fn"}                  1.34 ± 0.38             1.44 ± 0.44         1.33 ± 0.38    1.42 ± 0.44
  LDL cholesterol, mmol/L                                                 3.37 ± 0.64             3.32 ± 0.61         3.37 ± 0.67    3.32 ± 0.61
  Triglyceride, mmol/L                                                    1.64 ± 0.91             1.57 ± 0.78         1.59 ± 0.75    1.62 ± 0.90
  Systolic blood pressure, mmHg[\*](#tf1){ref-type="table-fn"}            138.5 ± 18.7            135.9 ± 16.3        138.8 ± 19.1   134.8 ± 16.3
  Diastolic blood pressure, mmHg                                          79.9 ± 11.8             78.5 ± 11.4         80.4 ± 11.6    78.3 ± 10.0

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

*p* \< 0.05.

The incidence of stroke and TIA, and each stroke subtype are shown in **[Table 2](#T2){ref-type="table"}**. The incidence of stroke and TIA was similar in the early cohort and in the late cohort (2.48 vs. 2.78%/year, *p* = 0.42). The incidence of atherothrombotic stroke was significantly higher in the early cohort compared with the late cohort among control patients (0.88 vs. 0.39%/year, *p* = 0.049). The incidences of any other stroke subtypes were similar in the early cohort and in the late cohort among patients with pravastatin.

###### Incidence of primary or secondary outcomes

  Incidence of each outcome                Pravastatin *n* = 793   Control *n* = 785                
  ---------------------------------------- ----------------------- ------------------- ------------ ------------
  Primary outcome                                                                                   
      Stroke and TIA, n (%)                53 (12.4)               39 (10.6)           52 (12.5)    44 (12.0)
          Incidence, 100 person-year       2.74                    2.36                2.70         2.60
                                                                                                    
  Secondary outcomes                                                                                
      All Strokes, n (%)                   47 (11.0)               38 (10.4)           49 (11.8)    41 (11.1)
          Incidence, 100 person-year       2.40                    2.29                2.53         2.41
      Atherothrombotic infarction, n (%)   5 (1.2)                 3 (0.8)             18 (4.3)     7 (1.9)
          Incidence, 100 person-year       0.24                    0.17                0.88         0.39
      Lacunar infarction, n (%)            26 (6.1)                21 (5.7)            20 (4.8)     18 (4.9)
          Incidence, 100 person-year       1.29                    1.23                1.00         1.03
      Cardioembolic infarction, n (%)      5 (1.2)                 2 (0.5)             1 (0.2)      2 (0.5)
          Incidence, 100 person-year       0.24                    0.11                0.05         0.11
      Intracranial hemorrhage, n (%)       6 (1.4)                 6 (1.6)             8 (1.9)      4 (1.1)
          Incidence, 100 person-year       0.29                    0.34                0.39         0.22
      TIA, n (%)                           6 (1.4)                 2 (0.5)             4 (1.0)      4 (1.1)
          Incidence, 100 person-year       0.29                    0.11                0.19         0.22
      Myocardial infarction, n (%)         3 (0.7)                 1 (0.3)             2 (0.5)      5 (1.4)
          Incidence, 100 person-year       0.14                    0.06                0.10         0.28
      Vascular accidents, n (%)            64 (15.0)               49 (13.4)           67 (16.1)    65 (17.7)
          Incidence, 100 person-year       3.37                    3.01                3.58         3.95
      Death, n (%)                         24 (5.6)                19 (5.2)            19 (4.6)     16 (4.3)
          Incidence, 100 person-year       1.14                    1.08                0.92         0.89
      Hospitalization, n (%)               128 (30.0)              107 (29.2)          113 (27.1)   119 (32.3)
          Incidence, 100 person-year       7.38                    7.30                6.55         7.84

TIA, transient ischemic attack

The HR of the primary outcome or each stroke subtype using the Cox proportional hazard model is shown in **[Table 3](#T3){ref-type="table"}**. Among patients in the early cohort, the incidence of stroke and TIA was similar in pravastatin groups compared with control groups (**[Fig. 1A](#F1){ref-type="fig"}**; 2.74 vs. 2.70%/year, *p* = 0.92, adjusted HR 1.02 \[95% CI 0.70 to 1.50\]). This was also the case among patients in the late cohort in pravastatin groups compared with control groups (**[Fig. 1A](#F1){ref-type="fig"}**; 2.36 vs. 2.60%/year, *p* = 0.64, adjusted HR 0.90 \[95% CI 0.59 to 1.39\]). By contrast, the incidence of atherothrombotic stroke was significantly lower in the pravastatin group compared with the control group among patients in the early cohort, (**[Fig. 1B](#F1){ref-type="fig"}**; 0.24 vs. 0.88%/year, *p* = 0.011, adjusted HR 0.30 \[95% CI 0.11 to 0.80\]). Among patients in the late cohort, the incidence of atherothrombotic stroke was not significantly reduced by pravastatin (**Fig. 2B**; 0.17 vs. 0.39%/year, *p* = 0.29, adjusted HR 0.49 \[95% CI 0.13 to 1.90\]). However, this difference of pravastatin effect on atherothrombotic stroke was not significantly interacted by the early or late cohort (*p* = 0.59). As for the occurrence of lacunar stroke, cardioembolic stroke, and intracranial hemorrhage, no significant differences were observed between the control groups enrolled within or later than 6 months after stroke onset. This was also the case for comparisons between pravastatin and control groups. Considering low follow-up rates at 6 year, even though analyzing the HR of primary outcome or each stroke subtype for early cohort or late cohort during 5 year observation, the similar results were obtained (data not shown).

###### The Cox proportional hazard model was used to estimate the hazard ratio (HR) and the 95% confidence interval (CI) for early cohort or late cohort.

  Incidence of each outcome                         Early cohort         Late cohort
  ------------------------------------------------- -------------------- -------------------
  Primary outcomes                                                       
      Stroke and TIA, HR (95%CI)                    1.02 (0.70--1.50)    0.90 (0.59--1.39)
                                                                         
  Secondary outcomes                                                     
      All Strokes, HR (95%CI)                       0.96 (0.64--1.43)    0.95 (0.61--1.48)
          Atherothrombotic infarction, HR (95%CI)   0.30 (0.11--0.80)    0.49 (0.13--1.90)
          Lacunar infarction, HR (95%CI)            1.28 (0.72--2.30)    1.17 (0.62--2.20)
          Cardioembolic infarction, HR (95%CI)      5.26 (0.61--45.06)   1.00 (0.14--7.08)
          Intracranial hemorrhage, HR (95%CI)       0.73 (0.25--2.11)    1.53 (0.43--5.44)
      TIA, HR (95%CI)                               1.41 (0.42--5.21)    0.51 (0.09--2.79)

Adjusted for the stratification factors at randomization: i.e., stroke subtype at baseline (atherothrombotic stroke vs. others), high BP (≥ 150/90 mmHg vs. not), and diabetes mellitus (absence vs. presence)

TIA, transient ischemic attack

![Kaplan-Meier curves for stroke and transient ischemic attack (A) and atherothrombotic stroke (B) in subjects enrolled within 6 months and later than 6 months from both pravastatin and control groups. In subjects enrolled within 6 months of stroke onset, the incidence of atherothrombotic stroke was significantly lower in the pravastatin group compared with that in the control group (B).](jat-25-262-g001){#F1}

Discussion
==========

The incidence of stroke and TIA was similar between pravastatin and control groups, regardless of whether enrollment occurred within or later than 6 months after the initial stroke event. However, the incidence of atherothrombotic stroke was more frequent in control subjects enrolled within 6 months of stroke onset. Treatment with pravastatin significantly reduced the incidence of atherothrombotic stroke if given within 6 months of the initial stroke.

In comparison with the baseline characteristics of the SPARCL trial^[@bib7])^, the parameters related to age and proportion of males, hypertension, diabetes mellitus, and subtype of small vessel disease were higher, whereas that of body mass index was lower, in our J-STARS population. In particular, the times from onset to enrollment were longer in the J-STARS study than the SPARCL trial^[@bib7])^. For example, the latter study included patients who had stroke or TIA only within 6 months prior to randomization, whereas the J-STARS study included patients with a history of non-cardioembolic ischemic stroke within the preceding 1--36 months. In the present study, we compared the incidence of stroke or TIA and stroke subtypes between patients enrolled within or later than 6 months after stroke onset. The systolic BP levels of subjects enrolled within 6 months were similar to the baseline levels of patients in the SPARCL trial. On the other hand, HDL cholesterol levels of patients in the J-STARS study were slightly higher than the baseline levels of those in the SPARCL trial. Furthermore, HDL cholesterol levels were lower and systolic BP levels were higher in the subjects enrolled within 6 months of stroke onset compared to those enrolled later than this time. These results suggest that subjects enrolled within 6 months after initial stroke onset were still under insufficient control of low HDL cholesterol and high systolic BP.

As reported in a previous epidemiological study^[@bib11])^, there is a frequent stroke recurrence within the first year of the initial stroke event. There were few studies to investigate the recurrent ischemic stroke subtype after non-cardioembolic stroke patients. In the present study, the incidences of lacunar infarction and atherothrombotic infarction were higher than those of other stroke subtypes among control patients. Interestingly, the incidence of atherothrombotic stroke was frequent in the early cohort compared with that in the late cohort among control patients, although the incidence of lacunar infarction was similar in the early cohort and in the late cohort. Our results might indicate that physicians should consider the high incidence of atherothrombotic stroke in early stage after initial noncardioembolic stroke onset. There was no significant difference in the incidence of stroke and TIA between the pravastatin group and control groups enrolled within or later than 6 months. However, the incidence of atherothrombotic stroke was significantly reduced in pravastatin-treated subjects in the early cohort, but not in the late cohort. Although interaction between statin efficacy and the timing of study entry was not significant, our results might suggest that early administration of statin treatment should be considered in order to reduce the risk of atherothrombotic stroke.

The current study has certain limitations. First, this was a sub-analysis of a PROBE designed study. Therefore, it is difficult to lead an assertive conclusion. Second, the small study sample size may not provide the statistical power required to adequately assess the effects of pravastatin with regard to time of enrollment. However, despite this small sample size, a statistically significant reduction of atherothrombotic stroke was obtained in the non-cardioembolic ischemic stroke subjects enrolled within 6 months (early cohort). Third, although there was no significant difference in the incidence rates of stroke and TIA between subjects enrolled within and later than 6 months, the incidence rates of atherothrombotic stroke were significantly lower in subjects enrolled later than 6 months. It may be because those subjects were without atherothrombotic stroke recurrence for 6 months. Finally, we could not evaluate the details of clinical course from the initial stroke onset to the time of study enrollment. Several factors (stroke severity, the management of several medications and so on) might affect that time period of study enrollment. Those factors might also influence the recurrence of stroke.

This post-hoc analysis showed that pravastatin treatment within 6 months of initial stroke onset reduces the incidence of atherothrombotic stroke in Japanese patients with non-cardioembolic stroke. Our findings might suggest a potential efficacy of earlier statin treatment in the prevention of recurrent stroke, although those associations were not conclusive.
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